Aspira Women's Health CFO Torsten Hombeck terminated for cause; CEO interim CFO

Aspira Women's Health Inc.

Dr. Torsten Hombeck terminated as CFO on June 27, 2024 due to personal civil matter unrelated to Company.
Termination deemed 'for cause' under employment agreement; no further payments beyond June 28, 2024 salary.
CEO Nicole Sandford assumes CFO duties on interim basis; search for permanent replacement underway.
Separate June 5, 2024 amendment had raised Hombeck's base salary to $375,000 and added Corporate Secretary title.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Nicole Sandford

Chief Financial Officer (interim)

AWHL · Aspira Women's Health Inc.

Effective: 2024-06-27
Filed: June 27, 2024, 7:59 PM ET

As of June 27, 2024, Nicole Sandford, the Company’s Chief Executive Officer, has taken over Dr. Hombeck’ s duties on an interim basis until a search for his replacement is completed.

Departed

Torsten Hombeck

Chief Financial Officer

AWHL · Aspira Women's Health Inc.

Effective: 2024-06-27
Successor: Nicole Sandford
Filed: June 27, 2024, 7:59 PM ET

On June 27, 2024, the Compensation Committee (the “Committee”) of Aspira Women’s Health Inc. (the “Company”) determined that a personal civil matter interfered with Dr. Torsten Hombeck’ s ability to continue to serve as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nicole Sandford was appointed as Chief Financial Officer (interim) at Aspira Women's Health Inc..

Action: appointed interim CFO
Role: Chief Financial Officer (interim)

Exact text from the filing

As of June 27, 2024, Nicole Sandford, the Company’s Chief Executive Officer, has taken over Dr. Hombeck’ s duties on an interim basis until a search for his replacement is completed.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Torsten Hombeck departed as Chief Financial Officer at Aspira Women's Health Inc..

Action: terminated for cause
Role: Chief Financial Officer

Exact text from the filing

On June 27, 2024, the Compensation Committee (the “Committee”) of Aspira Women’s Health Inc. (the “Company”) determined that a personal civil matter interfered with Dr. Torsten Hombeck’ s ability to continue to serve as the Company’s Chief Financial Officer.

View on SEC.gov

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-078612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.